Genmab ASGNMSF +1.77%95 Net Margin % is 5.92% as of Mar. 2026, which is 85% below its 10-year median of 38.98. GuruFocus rates GNMSF with a GF Score™ of 95/100 and a GF Value™ of $343.48 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, Genmab AS ranks better than 88.07% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Genmab AS's Net Income for the
three
months ended in Mar. 2026 was $53 Mil. Genmab AS's Revenue for the
three
months ended in Mar. 2026 was $896 Mil. Therefore, Genmab AS's net margin for the quarter that ended in Mar. 2026 was 5.92%.
The historical rank and industry rank for Genmab AS's Net Margin % or its related term are showing as below:
GNMSF'
s Net Margin % Range Over the Past 10 Years
Min: 21.04 Med: 38.98 Max: 65.36
Current: 21.04
GNMSF's Net Margin % is ranked better than 88.07% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs GNMSF: 21.04
Genmab AS (OTCPK:GNMSF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Genmab AS Net Margin % Related Terms
Genmab AS Net Margin % Historical Data
* Premium members only.
The historical data trend for Genmab AS's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNMSF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Genmab AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Net Margin % distribution charts can be found below:
* The bar in red indicates where Genmab AS's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (GNMSF) has a Net Margin % of 5.92% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Genmab AS and its competitors. This is 85% below median its historical median of 38.98. Over the past decade, Genmab AS's Net Margin % has ranged from 21.04 to 65.36. According to the industry distribution chart, Genmab AS ranks #113 out of 947 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Genmab AS's Net Margin % too high?
Genmab AS's current Net Margin % of 5.92% is 85% below median its 10-year median of 38.98. Over the past 10 years, this metric has ranged from a low of 21.04 to a high of 65.36. Based on the distribution chart, Genmab AS ranks #113 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #113 out of 947 companies for Net Margin %. This places Genmab AS in the top 12% of its industry — outperforming the majority of peers. Historically, Genmab AS's own Net Margin % has ranged from 21.04 to 65.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Genmab AS and its competitors. Genmab AS's current Net Margin % is 5.92%, which is 85% below median its own 10-year median of 38.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $343.48, compared to a current price of $262.00 — trading 23.7% below its estimated fair value. The current Net Margin % is 5.92%, which is 85% below median its 10-year median of 38.98. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Net Margin % is 5.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GNMSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $262.00 is trading 23.7% below its estimated GF Value™ of $343.48.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for GNMSF:
Net Margin %: 5.92% (85% below median its 10-year median of 38.98)
GF Value™: $343.48 vs. price of $262.00 (23.7% below fair value)
No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score
Get the complete analysis for GNMSF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNMSF has been successfully added to your 
